A Randomized, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KHK4827 in Healthy Volunteers and Subjects With Moderate to Severe Psoriasis
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Brodalumab (Primary) ; Brodalumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Dec 2011 New trial record